{
  "columnHierarchy": {
    "epochs": [
      {
        "id": "epoch_1",
        "name": "Maintenance Study",
        "instanceType": "StudyEpoch",
        "type": {
          "id": "4cd6cefd-88d4-4ff1-be67-852c1b9c4b34",
          "code": "C98780",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment Epoch",
          "instanceType": "Code"
        }
      }
    ],
    "encounters": [
      {
        "id": "enc_1",
        "name": "Placebo SC",
        "instanceType": "Encounter",
        "type": {
          "id": "81b43a59-6049-4eea-9057-f6c6b0ee41f5",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_2",
        "name": "Ustekinumab 90 mg SC q12w",
        "instanceType": "Encounter",
        "type": {
          "id": "ffc38c41-7e22-4b6f-b3d5-0769e1e8546c",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      },
      {
        "id": "enc_3",
        "name": "Ustekinumab 90 mg SC q8w",
        "instanceType": "Encounter",
        "type": {
          "id": "b3bcce35-edcc-4aad-a2a0-01adbe6c3968",
          "code": "C99156",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Scheduled Visit",
          "instanceType": "Code"
        },
        "epochId": "epoch_1"
      }
    ],
    "plannedTimepoints": [
      {
        "id": "pt_1",
        "visit": "Placebo",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_1",
        "instanceType": "Timing"
      },
      {
        "id": "pt_2",
        "visit": "Ustekinumab",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_2",
        "instanceType": "Timing"
      },
      {
        "id": "pt_3",
        "visit": "Ustekinumab",
        "epoch": "",
        "epochId": "",
        "day": "",
        "window": null,
        "encounterId": "enc_3",
        "instanceType": "Timing"
      }
    ]
  },
  "rowGroups": [
    {
      "id": "grp_1",
      "name": "Major secondary endpoints",
      "description": null,
      "childIds": [],
      "instanceType": "Activity",
      "activityNames": [
        "Maintenance of clinical response through Week 44",
        "Endoscopic healing at Week 44",
        "Clinical remission and not receiving concomitant corticosteroids at Week 44",
        "Maintenance of clinical remission through Week 44 among the subjects who had achieved clinical remission at maintenance baseline (both global and US definitions)"
      ]
    }
  ],
  "footnotes": [
    "a: Based on testing the SC ustekinumab 90 mg q8w group versus placebo at Î±=0.05 (2-sided).",
    "b: It is estimated that about 37% of subjects in the primary population (40 subjects per treatment group) will be in clinical remission at Week 0 of maintenance."
  ]
}